Frank Berthold

List of Publications by Year
in descending order

88 papers	6,749 citations	87888 38 h-index	62596 80 g-index
93 all docs	93 docs citations	93 times ranked	6807 citing authors

#	Article	IF	Citations
1	Advances in Risk Classification and Treatment Strategies for Neuroblastoma. Journal of Clinical Oncology, 2015, 33, 3008-3017.	1.6	637
2	Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature, 2015, 526, 700-704.	27.8	478
3	Neuroblastoma Screening at One Year of Age. New England Journal of Medicine, 2002, 346, 1047-1053.	27.0	381
4	Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncology, The, 2005, 6, 649-658.	10.7	350
5	Comparison of RNA-seq and microarray-based models for clinical endpoint prediction. Genome Biology, 2015, 16, 133.	8.8	325
6	Metabolic activity and clinical features of primary ganglioneuromas. Cancer, 2001, 91, 1905-1913.	4.1	281
7	Localized Infant Neuroblastomas Often Show Spontaneous Regression: Results of the Prospective Trials NB95-S and NB97. Journal of Clinical Oncology, 2008, 26, 1504-1510.	1.6	263
8	Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project. Journal of Clinical Oncology, 2011, 29, 3286-3292.	1.6	248
9	Clinical Significance of Tumor-Associated Inflammatory Cells in Metastatic Neuroblastoma. Journal of Clinical Oncology, 2012, 30, 3525-3532.	1.6	236
10	Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. Journal of Clinical Oncology, 2017, 35, 2580-2587.	1.6	219
11	A mechanistic classification of clinical phenotypes in neuroblastoma. Science, 2018, 362, 1165-1170.	12.6	213
12	Somatic mutations ofWNT/wingless signaling pathway components in primitive neuroectodermal tumors. International Journal of Cancer, 2001, 93, 445-449.	5.1	161
13	Consolidation Treatment With Chimeric Anti-GD2-Antibody ch14.18 in Children Older Than 1 Year With Metastatic Neuroblastoma. Journal of Clinical Oncology, 2004, 22, 3549-3557.	1.6	140
14	Cystic Craniopharyngioma: Long-term Results after Intracavitary Irradiation with Stereotactically Applied Colloidal ??-Emitting Radioactive Sources. Neurosurgery, 1997, 40, 263-270.	1.1	131
15	Role of Surgery in the Treatment of Patients With Stage 4 Neuroblastoma Age 18 Months or Older at Diagnosis. Journal of Clinical Oncology, 2013, 31, 752-758.	1.6	115
16	Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. BMC Cancer, 2011, 11, 21.	2.6	113
17	Treatment and outcomes of patients with relapsed, highâ€risk neuroblastoma: Results of German trials. Pediatric Blood and Cancer, 2011, 56, 578-583.	1.5	110
18	Treatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed. BMC Cancer, 2016, 16, 542.	2.6	110

#	Article	IF	Citations
19	Neuroblastoma. Drugs, 2000, 59, 1261-1277.	10.9	105
20	Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: A report from the International Neuroblastoma Risk Group Project. European Journal of Cancer, 2011, 47, 561-571.	2.8	94
21	The prognostic impact of functional imaging with 123I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: Results of the German Neuroblastoma Trial NB97. European Journal of Cancer, 2008, 44, 1552-1558.	2.8	88
22	Incidence, Survival, and Treatment of Localized and Metastatic Neuroblastoma in Germany 1979â€“2015. Paediatric Drugs, 2017, 19, 577-593.	3.1	86
23	Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial. Leukemia, 2018, 32, 1657-1669.	7.2	86
24	PHOX2B Is a Novel and Specific Marker for Minimal Residual Disease Testing in Neuroblastoma. Journal of Clinical Oncology, 2008, 26, 5443-5449.	1.6	83
25	Iodine-123 Metaiodobenzylguanidine Scintigraphy Scoring Allows Prediction of Outcome in Patients With Stage 4 Neuroblastoma: Results of the Cologne Interscore Comparison Study. Journal of Clinical Oncology, 2013, 31, 944-951.	1.6	80
26	Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers. Clinical Cancer Research, 2015, 21, 1904-1915.	7.0	80
27	Intensified External-Beam Radiation Therapy Improves the Outcome of Stage 4 Neuroblastoma in Children > 1 Year with Residual Local Disease. Strahlentherapie Und Onkologie, 2006, 182, 389-394.	2.0	76
28	2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors. Klinische Padiatrie, 2017, 229, 147-167.	0.6	76
29	Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group. Cancer, 2017, 123, 1095-1105.	4.1	75
30	THROMBOTECT â€“ a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica, 2019, 104, 756-765.	3.5	74
31	Detecting Minimal Residual Disease in Neuroblastoma: The Superiority of a Panel of Real-Time Quantitative PCR Markers. Clinical Chemistry, 2009, 55, 1316-1326.	3.2	65
32	Complete surgical resection improves outcome in INRG high-risk patients with localized neuroblastoma older than 18Âmonths. BMC Cancer, 2017, 17, 520.	2.6	63
33	Smallest region of overlapping deletion in 1p36 in human neuroblastoma: A 1 Mbp cosmid and PAC contig. Genes Chromosomes and Cancer, 2001, 31, 228-239.	2.8	61
34	Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial. Journal of Cancer Research and Clinical Oncology, 2007, 133, 653-661.	2.5	60
35	Prognostic significance of DNA di-tetraploidy in neuroblastoma. Medical and Pediatric Oncology, 2001, 36, 83-92.	1.0	57
36	The role of age in neuroblastoma risk stratification: the German, Italian, and children's oncology group perspectives. Cancer Letters, 2005, 228, 257-266.	7.2	48

#	Article	IF	Citations
37	Lack of immunocytological GD2 expression on neuroblastoma cells in bone marrow at diagnosis, during treatment, and at recurrence*. Pediatric Blood and Cancer, 2017, 64, 46-56.	1.5	44
38	FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma. Medical and Pediatric Oncology, 2003, 41, 30-35.	1.0	42
39	Transcription factor activating protein 2 beta (TFAP2B) mediates noradrenergic neuronal differentiation in neuroblastoma. Molecular Oncology, 2016, 10, 344-359.	4.6	36
40	Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR. Annals of Oncology, 2020, 31, 422-429.	1.2	36
41	Metastatic neuroblastoma in infancy: What does the pattern of metastases contribute to prognosis?. Medical and Pediatric Oncology, 2000, 35, 683-687.	1.0	35
42	Focal nodular hyperplasia of the liver in longterm survivors of neuroblastoma. European Journal of Radiology, 2010, 74, e1-e5.	2.6	35
43	Testicular and paratesticular involvement by metastatic neuroblastoma. Cancer, 2000, 88, 2636-2641.	4.1	33
44	Significance of clinical and biologic features in Stage 3 neuroblastoma: A report from the International Neuroblastoma Risk Group project. Pediatric Blood and Cancer, 2014, 61, 1932-1939.	1.5	32
45	Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation. British Journal of Cancer, 2018, 119, 282-290.	6.4	30
46	Telomerase Is a Prognostic Marker of Poor Outcome and a Therapeutic Target in Neuroblastoma. JCO Precision Oncology, 2019, 3, 1-20.	3.0	29
47	A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with highâ€risk neuroblastoma: An International Neuroblastoma Risk Group project. Pediatric Blood and Cancer, 2021, 68, e28794.	1.5	29
48	Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. Expert Opinion on Drug Discovery, 2017, 12, 1-11.	5.0	28
49	The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatric Blood and Cancer, 2020, 67, e28359.	1.5	28
50	Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients. JCI Insight, 2018, 3, .	5.0	28
51	Telomerase is a strong indicator for assessing the proneness to progression in neuroblastomas. Medical and Pediatric Oncology, 2000, 35, 651-655.	1.0	27
52	ecancermedicalscience. Ecancermedicalscience, 2014, 8, 463.	1.1	26
53	Immunotherapeutic strategies in neuroblastoma: Antitumoral activity of deglycosylated ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies. Medical and Pediatric Oncology, 2001, 36, 185-189.	1.0	26
54	Molecular Classification Substitutes for the Prognostic Variables Stage, Age, and MYCN Status in Neuroblastoma Risk Assessment. Neoplasia, 2017, 19, 982-990.	5.3	26

#	Article	IF	Citations
55	Rapid COJEC versus standard induction therapies for high-risk neuroblastoma. The Cochrane Library, 2016, 2016, CD010774.	2.8	25
56	Classification of neuroblastoma patients by published gene-expression markers reveals a low sensitivity for unfavorable courses of MYCN non-amplified disease. Cancer Letters, 2007, 250, 250-267.	7.2	22
57	Minimal residual disease detection in autologous stem cell grafts from patients with high risk neuroblastoma. Pediatric Blood and Cancer, 2015, 62, 1368-1373.	1.5	22
58	Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and withoutMYCN amplification. Cancer, 2002, 94, 854-861.	4.1	21
59	Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma. Pediatric Hematology and Oncology, 2017, 34, 308-319.	0.8	21
60	German neuroblastoma mass screening study at 12 months of age: statistical aspects and preliminary results. Medical and Pediatric Oncology, 1998, 31, 435-441.	1.0	16
61	Stereotactic intracavitary brachytherapy with P-32 for cystic craniopharyngiomas in children. Strahlentherapie Und Onkologie, 2016, 192, 157-165.	2.0	15
62	Feasibility, Risk Profile and Diagnostic Yield of Stereotactic Biopsy in Children and Young Adults with Brain Lesions. Klinische Padiatrie, 2017, 229, 133-141.	0.6	14
63	Biochemical testing for neuroblastoma using plasma free 3â€Oâ€methyldopa, 3â€methoxytyramine, and normetanephrine. Pediatric Blood and Cancer, 2020, 67, e28081.	1.5	14
64	Lacking immunocytological GD2 expression in neuroblastoma: Report of 3 cases. Pediatric Blood and Cancer, 2005, 45, 195-201.	1.5	13
65	Correction factors for self-selection when evaluating screening programmes. Journal of Medical Screening, 2016, 23, 44-49.	2.3	12
66	A new risk score for patients after first recurrence of stage 4 neuroblastoma aged â‰¥18Âmonths at first diagnosis. Cancer Medicine, 2019, 8, 7236-7243.	2.8	12
67	Î³-secretase inhibitor I inhibits neuroblastoma cells, with NOTCH and the proteasome among its targets. Oncotarget, 2016, 7, 62799-62813.	1.8	12
68	Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients. European Journal of Cancer, 2016, 54, 149-158.	2.8	10
69	Population-based and controlled study to evaluate neuroblastoma screening at one year of age in Germany: Interim results. Medical and Pediatric Oncology, 2000, 35, 701-704.	1.0	9
70	Clinical Presentation. , 2005, , 63-85.		9
71	Lead-time and overdiagnosis estimation in neuroblastoma screening. Statistics in Medicine, 2003, 22, 2877-2892.	1.6	8
72	Computer-Based Exercise Program: Effects of a 12-Week Intervention on Mood and Fatigue in Pediatric Patients With Cancer. Clinical Journal of Oncology Nursing, 2017, 21, E280-E286.	0.6	7

#	Article	IF	Citations
73	Can we optimise doxorubicin treatment regimens for children with cancer? Pharmacokinetic simulations and a Delphi consensus procedure. BMC Pharmacology & Toxicology, 2020, 21, 37.	2.4	7
74	Are network growth and the contributions to congresses associated with publication success? A pediatric oncology model. PLoS ONE, 2019, 14, e0210994.	2.5	6
75	Preclinical and clinical aspects on the use of amifostine as chemoprotectorin neuroblastoma patients. Medical and Pediatric Oncology, 2001, 36, 199-202.	1.0	5
76	Neuroblastoma Screening at 1 Year of Age: The Final Results of a Controlled Trial. JNCI Cancer Spectrum, 2021, 5, pkab041.	2.9	5
77	Asymmetric salivary gland123I-meta-iodobenzylguanidine uptake in a patient with cervical neuroblastoma and horner syndrome. Medical and Pediatric Oncology, 2001, 36, 489-490.	1.0	4
78	Clinical and molecular characterization of patients with stage 4(M) neuroblastoma aged less than 18Âmonths without MYCN amplification. Pediatric Blood and Cancer, 2021, 68, e29038.	1.5	4
79	Plasma Neurotensin: Lack of a Differentiation and Tumor Marker in Children with Neuroblastoma. Pediatric Hematology and Oncology, 1992, 9, 269-272.	0.8	3
80	Retrospective analysis of relapsed abdominal high-risk neuroblastoma. Journal of Pediatric Surgery, 2018, 53, 558-566.	1.6	3
81	The reliability of bone marrow cytology as response criterion in metastatic neuroblastoma. Pediatric Blood and Cancer, 2021, 68, e28819.	1.5	2
82	Confirmatory adaptive group sequential designs for singleâ€arm phase II studies with multiple timeâ€toâ€event endpoints. Biometrical Journal, 2022, 64, 312-342.	1.0	2
83	Metastatic neuroblastoma in infancy: What does the pattern of metastases contribute to prognosis?. , 2000, 35, 683.		2
84	Genetic Alterations and Resectability Predict Outcome in Patients with Neuroblastoma Assigned to High-Risk Solely by MYCN Amplification. Cancers, 2021, 13, 4360.	3.7	1
85	Hypercalcemia is a frequent side effect of 13â€•cis â€•retinoic acid treatment in patients with highâ€risk neuroblastoma. Pediatric Blood and Cancer, 2021, , e29374.	1.5	1
86	From a single meeting to a scientific community: Quantification of the â€œAdvances in Neuroblastoma Research Associationâ€•network. Pediatric Blood and Cancer, 2019, 66, e27696.	1.5	0
87	Solide Tumoren. , 2007, , 805-870.		0
88	Response to Front-Line Imatinib Treatment in Children and Adolescents with CML - Data from a Large Pediatric Cohort. Blood, 2017, 130, 898-898.	1.4	0